TME Pharma: Promising Results Against Glioblastoma Published in Nature Communications
TME Pharma announced on Thursday the publication in Nature Communications of the results of its GLORIA trial, highlighting a significantly higher overall survival for patients with glioblastoma treated with the NOX-A12 triple therapy. However, the translation of these clinical data into a marketed product is still dependent on the signing of a strategic partnership agreement, which the company is actively pursuing.
Detailed Study Results
The GLORIA trial, a phase 1/2 study conducted by TME Pharma, evaluated the triple therapy combining NOX-A12, radiotherapy, and anti-VEGF (bevacizumab) in patients with chemotherapy-resistant glioblastoma with residual tumor after surgery. According to the article published in Nature Communications, the overall survival of patients treated with the NOX-A12 triple therapy was significantly higher than that of two distinct cohorts of similar patients who received standard treatment outside the trial. The authors also noted that the cautious design of the trial suggests that the study 'probably underestimates survival compared to most contemporary trials'.
Expansion of the GLORIA Trial
TME Pharma has modified its GLORIA trial to include an additional 100 patients in a randomized and controlled phase 2 part comprising five additional arms (arms D to H). This extension aims to evaluate three different doses of NOX-A12 combined with radiotherapy, one dose of NOX-A12 with radiotherapy alone, and the standard treatment. The launch of this phase 2 is planned once the appropriate partnerships have been established. The company remains committed to finding a strategic partner to license NOX-A12 for marketing authorization. Since January 2026, TME Pharma has been actively pursuing discussions with potential partners.
Financial Stability and Strategic Planning
TME Pharma has sufficient cash reserves extending now until the second quarter of 2027, giving the company the necessary flexibility to identify the optimal partnership for NOX-A12. According to CEO Diede van den Ouden, appointed in June 2025 and currently engaged in strategic restructuring, this time window positions the company to continue its negotiations under appropriate conditions. The company believes that the strategic partnership is the optimal path to advance NOX-A12 towards commercial success.
